Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...
The FDA has granted tentative approval for Basaglar (insulin glargine injection), produced by Eli Lilly and Boehringer Ingelheim's (BI) diabetes alliance, following litigation filed by Sanofi ...
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...
Proficio Capital Partners LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 30.2% in the fourth ...
Eli Lilly and Company (NYSE ... Olumiant for rheumatoid arthritis, Basaglar, Cymbalta for depressive disorder, and other products. The company has grown its revenue by 15.54% over the last 5 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback